{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:28Z","timestamp":1790742508634,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["SIDI\/2013\/007"],"award-info":[{"award-number":["SIDI\/2013\/007"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2702-8","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T08:51:00Z","timestamp":1527843060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations \u2013 results of a prematurely terminated study"],"prefix":"10.1186","volume":"19","author":[{"given":"Shirin","family":"Kalimuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne F. Z.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Pei","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Archuleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chien","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan Tong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny G. H.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"issue":"1","key":"2702_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2702_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1086\/596731","volume":"30","author":"D Ben-David","year":"2009","unstructured":"Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 2009;30(5):453\u201360.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"2702_CR3","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/cid\/cit614","volume":"58","author":"KA Rodvold","year":"2014","unstructured":"Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present and future. Clin Infect Dis. 2014;58(Suppl 1):S20\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2702_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2702_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","volume":"45","author":"AL Barry","year":"2001","unstructured":"Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 north American medical centers. Antimicrob Agents Chemother. 2001;45(6):1919\u201322.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2702_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/383472","volume":"38","author":"CF Carpenter","year":"2004","unstructured":"Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38(7):994\u20131000.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2702_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/cir764","volume":"54","author":"CL Moore","year":"2012","unstructured":"Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2702_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijantimicag.2012.10.019","volume":"41","author":"CW Cheng","year":"2013","unstructured":"Cheng CW, Hsu PC, Yang CC, Chang HJ, Siu LK, Wu TL, et al. Influence of early daptomycin therapy on treatment outcome of methicillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2013;41(3):293\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2702_CR9","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2702_CR10","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1128\/AAC.00227-16","volume":"60","author":"KC Claeys","year":"2016","unstructured":"Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2702_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/1745-6215-15-233","volume":"15","author":"S Kalimuddin","year":"2014","unstructured":"Kalimuddin S, Phillips R, Gandhi M, de Souza NN, Low JG, Archuleta S, et al. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial. Trials. 2014;15:233.","journal-title":"Trials"},{"issue":"11","key":"2702_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275\u20139.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2702_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2702_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1086\/600039","volume":"49","author":"DA Figueroa","year":"2009","unstructured":"Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177\u201380.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2702_CR15","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2702_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/313753","volume":"30","author":"JS Li","year":"2000","unstructured":"Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2702_CR17","first-page":"1375","volume":"69","author":"R Simon","year":"1985","unstructured":"Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12):1375\u201381.","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"2702_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4103\/0255-0857.148837","volume":"33","author":"W Chang","year":"2015","unstructured":"Chang W, Ma X, Gao P, Lv X, Lu H, Chen F. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian J Med Microbiol. 2015;33(2):262\u20136.","journal-title":"Indian J Med Microbiol"},{"issue":"5","key":"2702_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/cid\/cir858","volume":"54","author":"CE Miller","year":"2012","unstructured":"Miller CE, Batra R, Cooper BS, Patel AK, Klein J, Otter JA, et al. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2012;54(5):591\u2013600.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2702_CR20","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1128\/AAC.00616-09","volume":"53","author":"HS Sader","year":"2009","unstructured":"Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009;53(10):4127\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2702_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1128\/AAC.00939-06","volume":"51","author":"PA Moise","year":"2007","unstructured":"Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51(7):2582\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2702_CR22","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398\u2013402.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2702_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10156-010-0086-0","volume":"17","author":"Y Takesue","year":"2011","unstructured":"Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mug\/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17(1):52\u20137.","journal-title":"J Infect Chemother"},{"issue":"6","key":"2702_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755\u201371.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2702_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/jac\/dkq050","volume":"65","author":"YK Yoon","year":"2010","unstructured":"Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother. 2010;65(5):1015\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2702_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"2702_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/eurheartj\/ehl427","volume":"28","author":"EE Hill","year":"2007","unstructured":"Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. 2007;28(2):196\u2013203.","journal-title":"Eur Heart J"},{"issue":"Suppl 5","key":"2702_CR28","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1086\/533594","volume":"46","author":"E Rubinstein","year":"2008","unstructured":"Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S378\u201385.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2702_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/cid\/cit730","volume":"58","author":"BL Fries","year":"2014","unstructured":"Fries BL, Licitra C, Crespo A, Akhter K, Busowski MT, Salazar D, et al. Infectious diseases consultation and the management of Staphylococcus aureus bacteremia. Clin Infect Dis. 2014;58(4):598\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2702_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MD.0b013e3181b8fccb","volume":"88","author":"T Lahey","year":"2009","unstructured":"Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine. 2009;88(5):263\u20137.","journal-title":"Medicine"},{"issue":"3","key":"2702_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/infdis\/168.3.773","volume":"168","author":"TL O'Sullivan","year":"1993","unstructured":"O'Sullivan TL, Ruffing MJ, Lamp KC, Warbasse LH, Rybak MJ. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis. 1993;168(3):773\u20136.","journal-title":"J Infect Dis"},{"issue":"3","key":"2702_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/infdis\/157.3.502","volume":"157","author":"RE Polk","year":"1988","unstructured":"Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis. 1988;157(3):502\u20137.","journal-title":"J Infect Dis"},{"issue":"6","key":"2702_CR33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/infdis\/164.6.1180","volume":"164","author":"MR Wallace","year":"1991","unstructured":"Wallace MR, Mascola JR, Oldfield EC 3rd. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis. 1991;164(6):1180\u20135.","journal-title":"J Infect Dis"},{"issue":"2","key":"2702_CR34","doi-asserted-by":"publisher","first-page":"182.e1","DOI":"10.1016\/j.amjmed.2009.05.031","volume":"123","author":"KA Hazlewood","year":"2010","unstructured":"Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123(2):182.e1\u20137.","journal-title":"Am J Med"},{"issue":"5","key":"2702_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016;375(5):454\u201363.","journal-title":"N Engl J Med"},{"issue":"16","key":"2702_CR36","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","volume":"313","author":"SM Berry","year":"2015","unstructured":"Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619\u201320.","journal-title":"JAMA"},{"issue":"3","key":"2702_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1740774515626362","volume":"13","author":"BR Saville","year":"2016","unstructured":"Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13(3):358\u201366.","journal-title":"Clin Trials"},{"issue":"4","key":"2702_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrclinonc.2011.165","volume":"9","author":"DA Berry","year":"2011","unstructured":"Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011;9(4):199\u2013207.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2702-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2702-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2702-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:59:03Z","timestamp":1559350743000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2702-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2702"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2702-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"assertion":[{"value":"30 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was granted ethics approval by the Singhealth Centralized Institute Review Board (CIRB) (approval ID 2013\/846\/E). Written informed consent was obtained from all patients before enrolment into the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"305"}}